Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.70 |
| ▸ | ITGAV | P06756 | 2/20 | 0.70 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319924 | 0.93 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL8353596 | 0.93 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL3315770 | 0.93 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL3315868 | 0.91 | ITGB1 (0.85) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL3314959 | 0.90 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL4627302 | 0.90 | ITGB1 (0.69) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL3313321 | 0.90 | ITGB1 (0.69) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL1028109 | 0.88 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL4624067 | 0.88 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7ITGA2 | |
| SCHEMBL3313207 | 0.88 | ITGB1 (0.66) | ITGB1ITGAVITGA4ITGB7ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |